Whole Genome Reagent Kits compatible with an existing Illumina NextSeq 500 Desktop Sequencer

MARKET RESEARCH PURPOSES ONLY
NOT A REQUEST FOR PROPOSAL OR SOLICITATION

This is a sources sought to determine the availability and capability of small and large businesses in providing a Whole Genome Reagent Kits compatible with an existing Illumina NextSeq 500 Desktop Sequencer. The associated North American Industry Classification System (NAICS) Code is 334516- Analytical Laboratory Instrument Manufacturing; Small Business Size Standard is 500 employees.

Part I: General Information (Introduction/Background/Scope)

The US Food and Drug Administration (FDA), National Center for Toxicological Research (NCTR), Division of Genetic and Molecular Toxicology conducts basic and applied research to address specific high-priority issues related to the induction of genetic damage. The research is directed toward developing and validating new methods or improving existing methods for evaluating the toxicity of food additives, human and animal drugs, biological therapies, tobacco products, and medical devices.

Researchers utilize an Illumina NextSeq 500 Desktop Sequencer for the evaluation of Micro Nucleic Acid (miRNA) in blood for detection of chemical-induced carcinogenicity and require Whole Genome Reagent Kits compatible with the existing sequencing equipment.

Part II: Requirements

A. Reagent Kits
At a minimum the contractor shall provide:

• NexSeq 500 High Output v2, Whole Genome, Sequencing Reagent Kits, 300 cycles Illumina Catalog Number FC-404-2004 or equal, for an Illumina Desktop Sequencer, Model Number NextSeq 500, Serial Number NS500407

Qty 10 EA

Part III: Supporting Information

A. Place of Performance
U.S. Food and Drug Administration
National Center for Toxicological Research
3900 NCTR Road
Jefferson, AR 72079

B. Period of Performance
Delivery shall occur 60 calendar days (or less) from date of award.

Part IV: Instructions to Prospective Respondents

The offeror shall furnish sufficient information necessary for the Government to conclusively determine that the respondent is capable and otherwise qualified to provide the supplies identified herein. At a minimum, responses shall include the following:

~Business name and bio, DUNS number, business address, business website, business size status (i.e., SB, VOSB, SDVOSB, HUBZone SB, 8(a), SDB, WOSB, EDWOSB, LB), point of contact name, mailing address (if different from business address), phone number and email address;

~Past performance information for the Reagent Kits identified herein, or for the same or substantially similar supplies, to include technical literature, dollar value, client name, client address, client point of contact name, client point of contact mailing address (if different from that provided for client), client point of contact phone number, client point of contact email address, and name of the manufacturer (to include DUNS number and size status) if not the respondent;

~Descriptive literature, brochures, specifications, marketing material, etc. detailing the nature of the supplies the responding firm is regularly engaged in providing;

~If applicable, identification of the firm's GSA Schedule contract(s) by Schedule number and SINs that are applicable to this requirement;

~Although this is not a request for quote, informational pricing is encouraged;

The Government encourages any comments and/or suggestions from any interested party, regarding the specifications. While the Government will not respond directly to your comments and/or suggestions; we will consider them as we finalize the specifications in preparation for the forthcoming solicitation.

The Government is not responsible for locating or securing any information, not identified in the response.

Interested parties must respond with capability statements, which are due in person, by postal mail or email to the point of contact listed below on or before May 5, 2015 by 9:00 AM (Central Time in Jefferson, Arkansas) at the Food and Drug Administration, OO|OFBA|OAGS|DAP, Attn: Sondea Blair, 3900 NCTR Road, Bldg 50, Room 421, HFT‐320, Jefferson, AR 72079‐9502 or email sondea.blair@fda.hhs.gov. Reference Number 1147709 in all correspondence with the point of contact listed above.

Notice of Intent
Responses to this sources sought announcement will assist the Government in determining whether this requirement should be set aside for small business, made available to full and open competition or procured through other than full and open acquisition procedures.

Disclaimer and Important Notes
This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a combined synopsis/solicitation (No. FDA-15-223-SOL-1147709) may be published via FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation.

Confidentiality
No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).